

Hansa Medical

- PRESS RELEASE -
February 2, 2015

Hansa Medical AB takes up a 20 MSEK loan from principal shareholder Nexttobe AB

Hansa Medical AB takes up a 20 MSEK loan from Nexttobe AB, principal shareholder of Hansa Medical AB. The purpose of the loan is to strengthen the financial persistence of the company.

“Hansa Medical is at a very exciting stage. Following the clinical Phase I study conducted last year and the recently finalized clinical Phase IIa study in transplantation patients, we have received very strong response from the medical community and from industrial parties as well as from financial stakeholders. We will now evaluate the best development path forward in order for IdeS to become a registered pharmaceutical, and in which indications. In parallel, we evaluate several types of industrial collaborations. In order to ensure our financial persistence during this period, we take up a loan from our principal shareholder Nexttobe AB. In this way I would like to thank Nexttobe for their support.” says Fredrik Lindgren, President and CEO at Hansa Medical AB.

The interest rate of the loan follows conditions on the market. The loan provider is allowed to demand repayment at the end of 2015.

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on NASDAQ First North in Stockholm with Remium Nordic AB as Certified Adviser. Major shareholders are Farstorps Gård AB and Nexttobe AB.

About IdeS

IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and efficiently. IdeS has been tested for safety and efficacy in numerous *in vitro* and *in vivo* models. During 2013, a Phase I clinical trial on 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favorable safety profile. During 2014 and 2015, a Phase II clinical trial in sensitized patients awaiting kidney transplantation has been conducted. Preliminary data shows that IdeS has very good efficacy in highly sensitized patients on the kidney transplant waitlist. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to levels acceptable for transplantation. In addition to transplantation, IdeS has potential indications within a variety of rare autoimmune diseases including anti-GBM disease. IdeS is protected by several patents and has been published in numerous peer review journals.

For further information, please contact:

Hansa Medical AB
Fredrik Lindgren, President and CEO
Mobile: +46 705 61 61 77
E-mail: fredrik.lindgren@hansamedical.com

www.hansamedical.com

The information in this press release is published in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was made available for publication on 2 February 2015, 14.00.